Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation

Hideyuki Nakajima; Masahiro Kamata; Yoshiki Okada; Makoto Ito; Ayu Watanabe; Saori Azuma; Hideaki Uchida; Shota Egawa; Chika Chijiwa; Azusa Hiura; Saki Fukaya; Kotaro Hayashi; Atsuko Fukuyasu; Takamitsu Tanaka; Takeko Ishikawa; Kazumitsu Sugiura; Yayoi Tada

doi:10.1684/ejd.2024.4711

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation

Hideyuki Nakajima
, Masahiro Kamata
, Yoshiki Okada
, Makoto Ito
, Ayu Watanabe
, Saori Azuma
, Hideaki Uchida
, Shota Egawa
, Chika Chijiwa
, Azusa Hiura
, Saki Fukaya
, Kotaro Hayashi
, Atsuko Fukuyasu
, Takamitsu Tanaka
, Takeko Ishikawa
, Kazumitsu Sugiura
, Yayoi Tada

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].

Original language	English
Pages (from-to)	324-325
Number of pages	2
Journal	European Journal of Dermatology
Volume	34
Issue number	3
DOIs	https://doi.org/10.1684/ejd.2024.4711
Publication status	Published - 01-05-2024
Externally published	Yes

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.1684/ejd.2024.4711

Cite this

Nakajima, H., Kamata, M., Okada, Y., Ito, M., Watanabe, A., Azuma, S., Uchida, H., Egawa, S., Chijiwa, C., Hiura, A., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T., Ishikawa, T., Sugiura, K., & Tada, Y. (2024). Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation. European Journal of Dermatology, 34(3), 324-325. https://doi.org/10.1684/ejd.2024.4711

@article{c8f0d34c57e34867aeba4f13535d976d,

title = "Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation",

abstract = "Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].",

author = "Hideyuki Nakajima and Masahiro Kamata and Yoshiki Okada and Makoto Ito and Ayu Watanabe and Saori Azuma and Hideaki Uchida and Shota Egawa and Chika Chijiwa and Azusa Hiura and Saki Fukaya and Kotaro Hayashi and Atsuko Fukuyasu and Takamitsu Tanaka and Takeko Ishikawa and Kazumitsu Sugiura and Yayoi Tada",

note = "Publisher Copyright: {\textcopyright} 2024 JLE.",

year = "2024",

month = may,

day = "1",

doi = "10.1684/ejd.2024.4711",

language = "English",

volume = "34",

pages = "324--325",

journal = "European Journal of Dermatology",

issn = "1167-1122",

publisher = "John Libbey",

number = "3",

}

Nakajima, H, Kamata, M, Okada, Y, Ito, M, Watanabe, A, Azuma, S, Uchida, H, Egawa, S, Chijiwa, C, Hiura, A, Fukaya, S, Hayashi, K, Fukuyasu, A, Tanaka, T, Ishikawa, T, Sugiura, K & Tada, Y 2024, 'Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation', European Journal of Dermatology, vol. 34, no. 3, pp. 324-325. https://doi.org/10.1684/ejd.2024.4711

TY - JOUR

T1 - Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation

AU - Nakajima, Hideyuki

AU - Kamata, Masahiro

AU - Okada, Yoshiki

AU - Ito, Makoto

AU - Watanabe, Ayu

AU - Azuma, Saori

AU - Uchida, Hideaki

AU - Egawa, Shota

AU - Chijiwa, Chika

AU - Hiura, Azusa

AU - Fukaya, Saki

AU - Hayashi, Kotaro

AU - Fukuyasu, Atsuko

AU - Tanaka, Takamitsu

AU - Ishikawa, Takeko

AU - Sugiura, Kazumitsu

AU - Tada, Yayoi

PY - 2024/5/1

Y1 - 2024/5/1

N2 - Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].

AB - Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].

UR - https://www.scopus.com/pages/publications/85199014525

UR - https://www.scopus.com/pages/publications/85199014525#tab=citedBy

U2 - 10.1684/ejd.2024.4711

DO - 10.1684/ejd.2024.4711

M3 - Letter

C2 - 39015980

AN - SCOPUS:85199014525

SN - 1167-1122

VL - 34

SP - 324

EP - 325

JO - European Journal of Dermatology

JF - European Journal of Dermatology

IS - 3

ER -

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this